There are around 200 people in England who are eligible for this treatment
There are around 200 people in England who are eligible for this treatment
Patients in the trial were those with unresectable hepatocellular carcinoma (HCC) who had not received systemic therapy treatment previously, and were not eligible for localised treatment
Entry closes on 22nd October – so don’t miss out on your chance to enter now
The ATTC is coordinated as part of the Cell and Gene Therapy Catapult, and operates within the NHS framework
Keytruda plus chemotherapy demonstrated superior overall survival rate in this patient population in the KEYNOTE-826 trial
The measures include a £250m ‘winter access fund’ from NHS England
26 experts have been appointed to join the Scientific Advisory Group on the Origins of Novel Pathogens (Sago)
In a Phase III study, the risk of death for advanced RCC patients was decreased by 34% with Cabometyx plus Opdivo treatment
Tolebrutinib reduced multiple sclerosis (MS) disease activity as measured by MRI
Conditional marketing authorisation granted for patients with advanced NSCLC with METex14 skipping alterations
Phase Ib CodeBreaK study evaluated Lumakras in over ten different investigational combination regimens
The new consumer healthcare company will be based at a newly built campus in Weybridge
AZD7442 cut the risk of severe COVID-19 and death by 50% in outpatients
Pharmacies saw increased customer demand during the pandemic, says UHY Hacker Young
‘Top-up’ doses of approved vaccines to be offered to ensure clinical trialists can travel abroad